

アリルアルコールの rasH2 マウスを用いた  
吸入による中期発がん性試験報告書

試験番号：0926

# TABLES

## TABLES

TABLE A	CONCENTRATIONS OF ALLYL ALCOHOL IN THE INHALATION CHAMBER
TABLE B1	SURVIVAL ANIMAL NUMBERS : MALE
TABLE B2	SURVIVAL ANIMAL NUMBERS : FEMALE
TABLE C1	CLINICAL OBSERVATION : MALE
TABLE C2	CLINICAL OBSERVATION : FEMALE
TABLE D1	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE
TABLE D2	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE
TABLE D3	BODY WEIGHT CHANGES : MALE
TABLE D4	BODY WEIGHT CHANGES : FEMALE
TABLE E1	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE
TABLE E2	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE
TABLE E3	FOOD CONSUMPTION CHANGES : MALE
TABLE E4	FOOD CONSUMPTION CHANGES : FEMALE
TABLE F1	URINALYSIS : MALE
TABLE F2	URINALYSIS : FEMALE
TABLE G1	HEMATOLOGY : MALE
TABLE G2	HEMATOLOGY : FEMALE

## TABLES (CONTINUED)

TABLE	H1	BIOCHEMISTRY : MALE
TABLE	H2	BIOCHEMISTRY : FEMALE
TABLE	I1	GROSS FINDINGS : MALE
TABLE	I2	GROSS FINDINGS : FEMALE
TABLE	J1	ORGAN WEIGHT, ABSOLUTE : MALE
TABLE	J2	ORGAN WEIGHT, ABSOLUTE : FEMALE
TABLE	K1	ORGAN WEIGHT, RELATIVE : MALE
TABLE	K2	ORGAN WEIGHT, RELATIVE : FEMALE
TABLE	L1	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : MALE
TABLE	L2	HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS : FEMALE
TABLE	M1	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : MALE
TABLE	M2	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS : FEMALE
TABLE	N1	HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : Jic:CB6F1-Tg rasH2@Jcl MALE MICE
TABLE	N2	HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : Jic:CB6F1-Tg rasH2@Jcl FEMALE MICE
TABLE	O	HISTOPATHOLOGICAL FINDINGS: METASTASIS OF TUMOR : MALE

## TABLES (CONTINUED)

TABLE P1 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: MALE

TABLE P2 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS  
: FEMALE

TABLE Q1 CAUSE OF DEATH : MALE

TABLE Q2 CAUSE OF DEATH : FEMALE

TABLE A

CONCENTRATIONS OF ALLYL ALCOHOL  
IN THE INHALATION CHAMBER

TABLE A      CONCENTRATIONS OF ALLYL ALCOHOL IN THE  
INHALATION CHAMBER

Group Name	Concentration (ppm)	
	Mean $\pm$ S.D.	
Control	0.00 $\pm$ 0.00	
0.15 ppm	0.15 $\pm$ 0.00	
0.5 ppm	0.50 $\pm$ 0.01	
1.5 ppm	1.49 $\pm$ 0.01	(0.99 $\pm$ 0.01) <sup>1)</sup>

1) This value is the measured concentration of allyl alcohol in the inhalation chamber for the first three exposures set at the target concentration of 1 ppm.

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0926

SURVIVAL ANIMAL NUMBERS

ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)

REPORT TYPE : A1 27

SEX : MALE

PAGE : 1

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
0.15 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
0.5 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1.5 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

(HAN360)

BAIS6



STUDY NO. : 0926

SURVIVAL ANIMAL NUMBERS

ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)

REPORT TYPE : A1 27

SEX : MALE

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
0.15 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0
0.5 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1.5 ppm	25	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0	24/25 96.0
		Number of survival/ Number of effective animals Survival rate(%)													

**TABLE B2**

**SURVIVAL ANIMAL NUMBERS : FEMALE**

STUDY NO. : 0926

SURVIVAL ANIMAL NUMBERS

ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)

REPORT TYPE : A1 27

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
0.15 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
0.5 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1.5 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

STUDY NO. : 0926

SURVIVAL ANIMAL NUMBERS

ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)

REPORT TYPE : A1 27

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks)													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
0.15 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	24/25 96.0	24/25 96.0	24/25 96.0
0.5 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
1.5 ppm	25	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0	25/25 100.0
		Number of survival/ Number of effective animals Survival rate(%)													

TABLE C1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 1

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	0.15 ppm	24	24	24	24	24	24	24	24	24	24	24	24	24	24
	0.5 ppm	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	1.5 ppm	25	25	25	25	25	25	25	25	25	25	25	24	24	24

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : MALE

PAGE : 2

Clinical sign	Group Name	Administration Week-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
		1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	1	1	1	1	1	1	1
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	1	1	1	1	1	1	1	1	1	1	1	1
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	1	1	1	1	1	1	1	1	1	1	1	1
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	24	24	24	24	24	24	24
	0.15 ppm	24	24	24	24	24	24	24	24	24	24	24	24
	0.5 ppm	25	25	25	25	25	25	25	25	25	25	25	25
	1.5 ppm	24	24	24	24	24	24	24	24	24	24	24	24

(HAN190)

BAIS 6

**TABLE C2**

**CLINICAL OBSERVATION : FEMALE**



STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 3

Clinical sign	Group Name	Administration Week-day													
		1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
		1	1	1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	0.15 ppm	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	0.5 ppm	25	25	25	25	25	25	25	25	25	25	25	25	25	25
	1.5 ppm	25	25	25	25	25	25	25	25	25	25	25	25	25	25

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1 26

CLINICAL OBSERVATION (SUMMARY)  
 ALL ANIMALS

SEX : FEMALE

PAGE : 4

Clinical sign	Group Name	Administration Week-day											
		15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7
		1	1	1	1	1	1	1	1	1	1	1	1
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	1	1
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	1	1	1	1	1	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
CICATRIX	Control	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	1	1	1
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
VAGINAL PROLAPSE	Control	0	0	0	0	0	0	0	0	0	0	0	0
	0.15 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	0.5 ppm	0	0	0	0	0	0	0	0	0	0	0	0
	1.5 ppm	0	0	0	0	1	1	1	1	1	1	1	1
NON REMARKABLE	Control	25	25	25	25	25	25	25	25	25	25	25	25
	0.15 ppm	25	25	25	25	24	24	24	24	24	24	23	23
	0.5 ppm	25	25	25	25	25	25	25	25	25	25	25	25
	1.5 ppm	25	25	25	25	24	24	24	24	24	24	24	24

TABLE D1

BODY WEIGHT CHANGES AND  
SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week-Day on Study	Control		0.15 ppm			0.5 ppm			1.5 ppm		
	Av. Wt.	No. of Surviv. <25>	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.
0-0	25.6 (25)	25/25	25.6 (25)	100	25/25	25.6 (25)	100	25/25	25.6 (25)	100	25/25
1-7	26.0 (25)	25/25	26.0 (25)	100	25/25	25.6 (25)	98	25/25	24.7 (25)	95	25/25
2-7	27.0 (25)	25/25	26.6 (25)	99	25/25	26.2 (25)	97	25/25	25.2 (25)	93	25/25
3-7	27.8 (25)	25/25	27.5 (25)	99	25/25	27.2 (25)	98	25/25	25.4 (25)	91	25/25
4-7	28.4 (25)	25/25	28.1 (25)	99	25/25	27.6 (25)	97	25/25	25.7 (25)	90	25/25
5-7	29.1 (25)	25/25	28.6 (25)	98	25/25	28.2 (25)	97	25/25	26.1 (25)	90	25/25
6-7	29.6 (25)	25/25	29.5 (25)	100	25/25	29.1 (25)	98	25/25	26.6 (25)	90	25/25
7-7	30.3 (25)	25/25	30.2 (25)	100	25/25	29.3 (25)	97	25/25	26.8 (25)	88	25/25
8-7	30.7 (25)	25/25	30.2 (25)	98	25/25	29.7 (25)	97	25/25	27.3 (25)	89	25/25
9-7	31.0 (25)	25/25	30.6 (25)	99	25/25	30.2 (25)	97	25/25	27.6 (25)	89	25/25
10-7	31.2 (25)	25/25	30.9 (25)	99	25/25	30.2 (25)	97	25/25	27.4 (25)	88	25/25
11-7	31.6 (25)	25/25	31.1 (25)	98	25/25	30.5 (25)	97	25/25	27.6 (25)	87	25/25
12-7	31.9 (25)	25/25	31.4 (25)	98	25/25	31.1 (25)	97	25/25	28.0 (25)	88	25/25
13-7	32.0 (25)	25/25	32.0 (25)	100	25/25	31.3 (25)	98	25/25	27.9 (25)	87	25/25
14-7	32.3 (25)	25/25	31.9 (25)	99	25/25	31.4 (25)	97	25/25	28.1 (24)	87	24/25
15-7	32.4 (25)	25/25	32.1 (25)	99	25/25	31.7 (25)	98	25/25	28.3 (24)	87	24/25
16-7	32.8 (25)	25/25	32.4 (25)	99	25/25	31.6 (25)	96	25/25	28.3 (24)	86	24/25
17-7	32.8 (25)	25/25	32.1 (25)	98	25/25	32.0 (25)	98	25/25	28.3 (24)	86	24/25
18-7	32.9 (25)	25/25	32.2 (25)	98	25/25	31.9 (25)	97	25/25	28.3 (24)	86	24/25
19-7	33.1 (25)	25/25	32.7 (25)	99	25/25	32.5 (25)	98	25/25	28.8 (24)	87	24/25
20-7	33.7 (24)	24/25	33.0 (25)	98	25/25	32.8 (25)	97	25/25	29.0 (24)	86	24/25
21-7	33.7 (24)	24/25	33.0 (25)	98	25/25	32.7 (25)	97	25/25	28.9 (24)	86	24/25
22-7	34.2 (24)	24/25	33.5 (25)	98	25/25	33.3 (25)	97	25/25	29.0 (24)	85	24/25
23-7	34.1 (24)	24/25	33.7 (25)	99	25/25	33.1 (25)	97	25/25	29.0 (24)	85	24/25
24-7	34.7 (24)	24/25	34.1 (25)	98	25/25	33.4 (25)	96	25/25	29.2 (24)	84	24/25
25-7	34.7 (24)	24/25	34.2 (25)	99	25/25	33.7 (25)	97	25/25	29.3 (24)	84	24/25
26-7	34.9 (24)	24/25	34.2 (25)	98	25/25	33.9 (25)	97	25/25	29.1 (24)	83	24/25

< >:No. of effective animals, ( ):No. of measured animals Av. Wt. : g

**TABLE D2**

**BODY WEIGHT CHANGES AND  
SURVIVAL ANIMAL NUMBERS : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week-Day on Study	Control		0.15 ppm			0.5 ppm			1.5 ppm		
	Av. Wt.	No. of Surviv. <25>	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.	Av. Wt.	% of cont. <25>	No. of Surviv.
0-0	20.2 (25)	25/25	20.2 (25)	100	25/25	20.2 (25)	100	25/25	20.2 (25)	100	25/25
1-7	20.5 (25)	25/25	20.4 (25)	100	25/25	20.2 (25)	99	25/25	19.8 (25)	97	25/25
2-7	20.6 (25)	25/25	20.5 (25)	100	25/25	20.6 (25)	100	25/25	20.0 (25)	97	25/25
3-7	21.3 (25)	25/25	21.2 (25)	100	25/25	20.8 (25)	98	25/25	20.1 (25)	94	25/25
4-7	21.7 (25)	25/25	21.8 (25)	100	25/25	21.6 (25)	100	25/25	20.4 (25)	94	25/25
5-7	22.8 (25)	25/25	22.8 (25)	100	25/25	22.6 (25)	99	25/25	21.1 (25)	93	25/25
6-7	23.4 (25)	25/25	23.3 (25)	100	25/25	23.2 (25)	99	25/25	21.5 (25)	92	25/25
7-7	23.5 (25)	25/25	23.3 (25)	99	25/25	23.2 (25)	99	25/25	22.2 (25)	94	25/25
8-7	23.6 (25)	25/25	23.3 (25)	99	25/25	23.4 (25)	99	25/25	22.0 (25)	93	25/25
9-7	23.6 (25)	25/25	24.0 (25)	102	25/25	23.5 (25)	100	25/25	22.7 (25)	96	25/25
10-7	23.6 (25)	25/25	23.8 (25)	101	25/25	23.4 (25)	99	25/25	22.6 (25)	96	25/25
11-7	24.0 (25)	25/25	24.1 (25)	100	25/25	23.7 (25)	99	25/25	23.0 (25)	96	25/25
12-7	24.0 (25)	25/25	24.1 (25)	100	25/25	24.5 (25)	102	25/25	23.3 (25)	97	25/25
13-7	24.2 (25)	25/25	24.5 (25)	101	25/25	24.5 (25)	101	25/25	23.3 (25)	96	25/25
14-7	24.5 (25)	25/25	24.9 (25)	102	25/25	24.4 (25)	100	25/25	23.3 (25)	95	25/25
15-7	24.5 (25)	25/25	24.7 (25)	101	25/25	24.9 (25)	102	25/25	23.6 (25)	96	25/25
16-7	24.8 (25)	25/25	24.9 (25)	100	25/25	24.9 (25)	100	25/25	23.7 (25)	96	25/25
17-7	24.8 (25)	25/25	25.2 (25)	102	25/25	24.8 (25)	100	25/25	23.9 (25)	96	25/25
18-7	24.6 (25)	25/25	24.9 (25)	101	25/25	24.4 (25)	99	25/25	23.8 (25)	97	25/25
19-7	24.9 (25)	25/25	25.5 (25)	102	25/25	25.2 (25)	101	25/25	24.3 (25)	98	25/25
20-7	25.2 (25)	25/25	25.5 (25)	101	25/25	25.0 (25)	99	25/25	24.2 (25)	96	25/25
21-7	25.7 (25)	25/25	25.3 (25)	98	25/25	25.6 (25)	100	25/25	24.1 (25)	94	25/25
22-7	25.6 (25)	25/25	25.8 (25)	101	25/25	25.3 (25)	99	25/25	24.5 (25)	96	25/25
23-7	26.1 (25)	25/25	25.7 (25)	98	25/25	25.5 (25)	98	25/25	24.4 (25)	93	25/25
24-7	25.6 (25)	25/25	25.6 (25)	100	25/25	25.9 (25)	101	25/25	24.3 (25)	95	25/25
25-7	25.8 (25)	25/25	26.5 (24)	103	24/25	25.5 (25)	99	25/25	24.3 (25)	94	25/25
26-7	26.3 (25)	25/25	26.8 (24)	102	24/25	26.0 (25)	99	25/25	24.5 (25)	93	25/25

< >:No. of effective animals, ( ):No. of measured animals Av. Wt. : g

TABLE D3

BODY WEIGHT CHANGES : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		2-7		3-7		4-7		5-7		6-7	
	0-0		1-7											
Control	25.6±	1.3	26.0±	1.4	27.0±	1.3	27.8±	1.4	28.4±	1.5	29.1±	1.6	29.6±	1.6
0.15 ppm	25.6±	1.3	26.0±	1.4	26.6±	1.4	27.5±	1.4	28.1±	1.8	28.6±	1.8	29.5±	1.7
0.5 ppm	25.6±	1.4	25.6±	1.3	26.2±	1.2	27.2±	1.2	27.6±	1.5	28.2±	1.4	29.1±	1.5
1.5 ppm	25.6±	1.3	24.7±	1.3**	25.2±	1.5**	25.4±	1.4**	25.7±	1.4**	26.1±	1.6**	26.6±	1.5**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		9-7	10-7	11-7	12-7	13-7
	7-7	8-7	8-7	9-7					
Control	30.3± 1.7	30.7± 1.8	31.0± 2.0	31.2± 2.0	31.6± 2.0	31.9± 2.2	32.0± 2.4		
0.15 ppm	30.2± 1.9	30.2± 2.1	30.6± 2.0	30.9± 2.0	31.1± 2.0	31.4± 2.1	32.0± 2.3		
0.5 ppm	29.3± 1.8	29.7± 1.8	30.2± 1.9	30.2± 2.2	30.5± 2.3	31.1± 2.6	31.3± 2.5		
1.5 ppm	26.8± 1.5**	27.3± 1.5**	27.6± 1.4**	27.4± 1.5**	27.6± 1.6**	28.0± 1.7**	27.9± 1.8**		

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day							
	14-7	15-7	16-7	17-7	18-7	19-7	20-7	
Control	32.3± 2.7	32.4± 2.7	32.8± 2.8	32.8± 2.8	32.9± 2.9	33.1± 3.0	33.7± 3.0	
0.15 ppm	31.9± 2.4	32.1± 2.3	32.4± 2.3	32.1± 2.1	32.2± 2.5	32.7± 2.5	33.0± 2.7	
0.5 ppm	31.4± 2.6	31.7± 2.6	31.6± 2.8	32.0± 2.9	31.9± 3.1	32.5± 3.2	32.8± 3.3	
1.5 ppm	28.1± 1.5**	28.3± 1.5**	28.3± 1.5**	28.3± 1.7**	28.3± 1.8**	28.8± 1.9**	29.0± 1.9**	

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		23-7		24-7		25-7		26-7	
	21-7		22-7									
Control	33.7±	3.0	34.2±	3.4	34.1±	3.4	34.7±	3.5	34.7±	3.3	34.9±	3.1
0.15 ppm	33.0±	2.7	33.5±	2.5	33.7±	2.8	34.1±	3.1	34.2±	2.9	34.2±	2.8
0.5 ppm	32.7±	3.4	33.3±	3.4	33.1±	3.2	33.4±	3.3	33.7±	3.4	33.9±	3.1
1.5 ppm	28.9±	1.9**	29.0±	1.8**	29.0±	2.0**	29.2±	2.0**	29.3±	2.0**	29.1±	2.0**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE D4**

**BODY WEIGHT CHANGES : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		2-7		3-7		4-7		5-7		6-7	
	0-0		1-7											
Control	20.2±	1.2	20.5±	1.2	20.6±	1.1	21.3±	1.2	21.7±	1.1	22.8±	1.2	23.4±	1.1
0.15 ppm	20.2±	1.2	20.4±	1.1	20.5±	1.0	21.2±	1.5	21.8±	1.2	22.8±	1.3	23.3±	0.9
0.5 ppm	20.2±	1.2	20.2±	1.1	20.6±	1.1	20.8±	1.0	21.6±	1.4	22.6±	1.3	23.2±	1.4
1.5 ppm	20.2±	1.2	19.8±	1.4	20.0±	1.4	20.1±	1.3**	20.4±	1.1**	21.1±	1.3**	21.5±	1.3**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		9-7	10-7	11-7	12-7	13-7
	7-7	8-7	8-7	9-7					
Control	23.5± 1.2	23.6± 1.2	23.6± 1.2	23.6± 1.1	24.0± 1.0	24.0± 1.1	24.2± 1.5		
0.15 ppm	23.3± 1.3	23.3± 1.2	24.0± 1.6	23.8± 1.4	24.1± 1.0	24.1± 1.4	24.5± 1.5		
0.5 ppm	23.2± 1.6	23.4± 1.5	23.5± 1.1	23.4± 1.3	23.7± 1.1	24.5± 1.5	24.5± 1.7		
1.5 ppm	22.2± 1.6**	22.0± 1.4**	22.7± 1.6	22.6± 1.4*	23.0± 1.4*	23.3± 1.4	23.3± 1.6		

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		14-7		15-7		16-7		17-7		18-7		19-7		20-7	
Control	24.5±	1.7	24.5±	1.2	24.8±	1.6	24.8±	1.6	24.6±	1.6	24.9±	1.5	25.2±	1.8				
0.15 ppm	24.9±	1.5	24.7±	1.6	24.9±	1.7	25.2±	1.7	24.9±	1.4	25.5±	1.9	25.5±	2.4				
0.5 ppm	24.4±	1.5	24.9±	1.4	24.9±	1.6	24.8±	1.9	24.4±	1.4	25.2±	1.5	25.0±	1.9				
1.5 ppm	23.3±	1.8*	23.6±	1.8	23.7±	1.9	23.9±	1.9	23.8±	2.1	24.3±	1.8	24.2±	1.8				

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration		week-day		23-7		24-7		25-7		26-7	
	21-7		22-7									
Control	25.7±	1.6	25.6±	1.7	26.1±	2.1	25.6±	1.5	25.8±	1.8	26.3±	2.0
0.15 ppm	25.3±	1.7	25.8±	1.8	25.7±	1.6	25.6±	1.3	26.5±	2.4	26.8±	2.7
0.5 ppm	25.6±	2.3	25.3±	2.0	25.5±	1.6	25.9±	1.7	25.5±	1.6	26.0±	1.5
1.5 ppm	24.1±	1.9**	24.5±	2.0	24.4±	2.2**	24.3±	1.9*	24.3±	2.1*	24.5±	2.3*

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



TABLE E1

FOOD CONSUMPTION CHANGES AND  
SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control		0.15 ppm			0.5 ppm			1.5 ppm		
	Av. FC.	No. of Surviv. <25>	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.
1-7	4.0 (25)	25/25	4.0 (25)	100	25/25	3.9 (25)	98	25/25	3.7 (25)	93	25/25
2-7	4.1 (25)	25/25	4.2 (25)	102	25/25	4.0 (25)	98	25/25	3.8 (25)	93	25/25
3-7	4.3 (25)	25/25	4.3 (25)	100	25/25	4.1 (25)	95	25/25	3.8 (25)	88	25/25
4-7	4.4 (25)	25/25	4.5 (25)	102	25/25	4.3 (25)	98	25/25	3.9 (25)	89	25/25
5-7	4.7 (25)	25/25	4.6 (25)	98	25/25	4.4 (25)	94	25/25	4.0 (25)	85	25/25
6-7	4.7 (25)	25/25	4.6 (25)	98	25/25	4.5 (25)	96	25/25	4.0 (25)	85	25/25
7-7	4.7 (25)	25/25	4.6 (25)	98	25/25	4.5 (25)	96	25/25	4.1 (25)	87	25/25
8-7	4.7 (25)	25/25	4.6 (25)	98	25/25	4.5 (25)	96	25/25	4.1 (25)	87	25/25
9-7	4.7 (25)	25/25	4.7 (25)	100	25/25	4.6 (25)	98	25/25	4.2 (25)	89	25/25
10-7	4.7 (25)	25/25	4.7 (25)	100	25/25	4.5 (25)	96	25/25	4.1 (25)	87	25/25
11-7	4.8 (25)	25/25	4.7 (25)	98	25/25	4.6 (25)	96	25/25	4.1 (25)	85	25/25
12-7	5.0 (25)	25/25	4.9 (25)	98	25/25	4.8 (25)	96	25/25	4.4 (25)	88	25/25
13-7	4.8 (25)	25/25	4.8 (25)	100	25/25	4.7 (25)	98	25/25	4.2 (25)	88	25/25
14-7	4.9 (25)	25/25	4.7 (25)	96	25/25	4.6 (25)	94	25/25	4.2 (24)	86	24/25
15-7	4.8 (25)	25/25	4.8 (25)	100	25/25	4.6 (25)	96	25/25	4.2 (24)	88	24/25
16-7	4.8 (25)	25/25	4.7 (25)	98	25/25	4.6 (25)	96	25/25	4.2 (24)	88	24/25
17-7	4.8 (25)	25/25	4.7 (25)	98	25/25	4.8 (25)	100	25/25	4.3 (24)	90	24/25
18-7	4.8 (25)	25/25	4.5 (25)	94	25/25	4.6 (25)	96	25/25	4.1 (24)	85	24/25
19-7	4.7 (25)	25/25	4.6 (25)	98	25/25	4.6 (25)	98	25/25	4.1 (24)	87	24/25
20-7	4.8 (24)	24/25	4.6 (25)	96	25/25	4.5 (25)	94	25/25	4.2 (24)	88	24/25
21-7	4.8 (24)	24/25	4.5 (25)	94	25/25	4.6 (25)	96	25/25	4.1 (24)	85	24/25
22-7	4.9 (24)	24/25	4.6 (25)	94	25/25	4.6 (25)	94	25/25	4.1 (24)	84	24/25
23-7	4.8 (24)	24/25	4.7 (25)	98	25/25	4.5 (25)	94	25/25	4.2 (24)	88	24/25
24-7	5.0 (24)	24/25	4.7 (25)	94	25/25	4.7 (25)	94	25/25	4.2 (24)	84	24/25
25-7	4.9 (24)	24/25	4.7 (25)	96	25/25	4.6 (25)	94	25/25	4.1 (24)	84	24/25
26-7	4.9 (24)	24/25	4.6 (25)	94	25/25	4.7 (25)	96	25/25	4.2 (24)	86	24/25

< >:No. of effective animals, ( ):No. of measured animals Av. FC. : g

**TABLE E2**

**FOOD CONSUMPTION CHANGES AND  
SURVIVAL ANIMAL NUMBERS : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week-Day on Study	Control		0.15 ppm			0.5 ppm			1.5 ppm		
	Av. FC.	No. of Surviv. <25>	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.	Av. FC.	% of cont. <25>	No. of Surviv.
1-7	3.3 (25)	25/25	3.4 (25)	103	25/25	3.4 (25)	103	25/25	3.2 (25)	97	25/25
2-7	3.5 (25)	25/25	3.5 (25)	100	25/25	3.5 (25)	100	25/25	3.2 (25)	91	25/25
3-7	3.7 (25)	25/25	3.9 (25)	105	25/25	3.8 (25)	103	25/25	3.4 (25)	92	25/25
4-7	4.1 (25)	25/25	4.3 (25)	105	25/25	4.3 (25)	105	25/25	3.7 (25)	90	25/25
5-7	4.7 (25)	25/25	4.7 (25)	100	25/25	4.5 (25)	96	25/25	3.9 (25)	83	25/25
6-7	4.4 (25)	25/25	4.6 (25)	105	25/25	4.5 (25)	102	25/25	3.9 (25)	89	25/25
7-7	4.4 (25)	25/25	4.9 (25)	111	25/25	4.7 (25)	107	25/25	4.1 (25)	93	25/25
8-7	4.4 (25)	25/25	4.5 (25)	102	25/25	4.6 (25)	105	25/25	4.1 (25)	93	25/25
9-7	4.5 (25)	25/25	4.9 (25)	109	25/25	4.7 (25)	104	25/25	4.1 (25)	91	25/25
10-7	4.4 (25)	25/25	4.6 (25)	105	25/25	4.7 (25)	107	25/25	4.1 (25)	93	25/25
11-7	4.6 (25)	25/25	4.8 (25)	104	25/25	4.8 (25)	104	25/25	4.3 (25)	93	25/25
12-7	4.9 (25)	25/25	4.8 (25)	98	25/25	5.1 (25)	104	25/25	4.4 (25)	90	25/25
13-7	4.7 (25)	25/25	4.8 (25)	102	25/25	5.0 (25)	106	25/25	4.2 (25)	89	25/25
14-7	4.7 (25)	25/25	4.8 (25)	102	25/25	4.7 (25)	100	25/25	4.1 (25)	87	25/25
15-7	4.7 (25)	25/25	4.8 (25)	102	25/25	4.9 (25)	104	25/25	4.1 (25)	87	25/25
16-7	4.6 (25)	25/25	4.7 (25)	102	25/25	4.9 (25)	107	25/25	4.1 (25)	89	25/25
17-7	4.7 (25)	25/25	4.7 (25)	100	25/25	4.9 (25)	104	25/25	4.2 (25)	89	25/25
18-7	4.3 (25)	25/25	4.3 (25)	100	25/25	4.7 (25)	109	25/25	3.9 (25)	91	25/25
19-7	4.4 (25)	25/25	4.6 (25)	105	25/25	4.8 (25)	109	25/25	4.0 (25)	91	25/25
20-7	4.4 (25)	25/25	4.3 (25)	98	25/25	4.5 (25)	102	25/25	3.9 (25)	89	25/25
21-7	4.6 (25)	25/25	4.4 (25)	96	25/25	4.9 (25)	107	25/25	4.0 (25)	87	25/25
22-7	4.4 (25)	25/25	4.5 (25)	102	25/25	4.7 (25)	107	25/25	4.1 (25)	93	25/25
23-7	4.7 (25)	25/25	4.4 (25)	94	25/25	4.7 (25)	100	25/25	4.0 (25)	85	25/25
24-7	4.3 (25)	25/25	4.3 (25)	100	25/25	4.6 (25)	107	25/25	4.0 (25)	93	25/25
25-7	4.6 (25)	25/25	4.6 (24)	100	24/25	4.5 (25)	98	25/25	4.1 (25)	89	25/25
26-7	4.6 (25)	25/25	4.5 (24)	98	24/25	4.6 (25)	100	25/25	4.0 (25)	87	25/25

< >:No. of effective animals, ( ) :No. of measured animals Av. FC. : g

TABLE E3

FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	4.0± 0.3	4.1± 0.2	4.3± 0.3	4.4± 0.3	4.7± 0.3	4.7± 0.3	4.7± 0.4
0.15 ppm	4.0± 0.3	4.2± 0.2	4.3± 0.3	4.5± 0.4	4.6± 0.4	4.6± 0.4	4.6± 0.5
0.5 ppm	3.9± 0.3	4.0± 0.2	4.1± 0.3	4.3± 0.3	4.4± 0.4*	4.5± 0.4	4.5± 0.4
1.5 ppm	3.7± 0.3**	3.8± 0.3**	3.8± 0.3**	3.9± 0.4**	4.0± 0.4**	4.0± 0.3**	4.1± 0.3**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	4.7± 0.3	4.7± 0.3	4.7± 0.3	4.8± 0.4	5.0± 0.4	4.8± 0.4	4.9± 0.4
0.15 ppm	4.6± 0.5	4.7± 0.5	4.7± 0.6	4.7± 0.6	4.9± 0.7	4.8± 0.6	4.7± 0.6
0.5 ppm	4.5± 0.4	4.6± 0.4	4.5± 0.4	4.6± 0.5	4.8± 0.5	4.7± 0.4	4.6± 0.4
1.5 ppm	4.1± 0.4**	4.2± 0.4**	4.1± 0.4**	4.1± 0.4**	4.4± 0.5**	4.2± 0.5**	4.2± 0.4**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Control	4.8± 0.4	4.8± 0.5	4.8± 0.4	4.8± 0.4	4.7± 0.4	4.8± 0.4	4.8± 0.5
0.15 ppm	4.8± 0.6	4.7± 0.6	4.7± 0.5	4.5± 0.6	4.6± 0.5	4.6± 0.5	4.5± 0.5
0.5 ppm	4.6± 0.4	4.6± 0.5	4.8± 0.4	4.6± 0.5	4.6± 0.4	4.5± 0.4	4.6± 0.5
1.5 ppm	4.2± 0.4**	4.2± 0.4**	4.3± 0.4**	4.1± 0.4**	4.1± 0.4**	4.2± 0.4**	4.1± 0.4**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett



STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)				
	22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Control	4.9± 0.5	4.8± 0.4	5.0± 0.4	4.9± 0.4	4.9± 0.4
0.15 ppm	4.6± 0.5	4.7± 0.5	4.7± 0.6	4.7± 0.5	4.6± 0.4
0.5 ppm	4.6± 0.4	4.5± 0.4	4.7± 0.4*	4.6± 0.4	4.7± 0.4
1.5 ppm	4.1± 0.4**	4.2± 0.5**	4.2± 0.4**	4.1± 0.4**	4.2± 0.4**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

**TABLE E4**

**FOOD CONSUMPTION CHANGES : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	3.3± 0.5	3.5± 0.3	3.7± 0.4	4.1± 0.5	4.7± 1.3	4.4± 0.4	4.4± 0.4
0.15 ppm	3.4± 0.3	3.5± 0.3	3.9± 0.6	4.3± 1.0	4.7± 1.0	4.6± 0.6	4.9± 1.1
0.5 ppm	3.4± 0.3	3.5± 0.3	3.8± 0.4	4.3± 0.4	4.5± 0.4	4.5± 0.4	4.7± 0.6*
1.5 ppm	3.2± 0.4	3.2± 0.4**	3.4± 0.3*	3.7± 0.4**	3.9± 0.4**	3.9± 0.4**	4.1± 0.7*

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	4.4± 0.4	4.5± 0.6	4.4± 0.4	4.6± 0.6	4.9± 1.2	4.7± 0.6	4.7± 0.6
0.15 ppm	4.5± 0.5	4.9± 0.9	4.6± 0.4	4.8± 0.5	4.8± 0.6	4.8± 0.6	4.8± 0.4
0.5 ppm	4.6± 0.5	4.7± 0.4	4.7± 0.5	4.8± 0.5	5.1± 0.7	5.0± 0.9	4.7± 0.6
1.5 ppm	4.1± 0.7	4.1± 0.4*	4.1± 0.4	4.3± 0.5*	4.4± 0.5	4.2± 0.5**	4.1± 0.5**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	15-7(7)	16-7(7)	17-7(7)	18-7(7)	19-7(7)	20-7(7)	21-7(7)
Control	4.7± 0.5	4.6± 0.5	4.7± 0.6	4.3± 0.5	4.4± 0.5	4.4± 0.5	4.6± 0.5
0.15 ppm	4.8± 0.6	4.7± 0.4	4.7± 0.4	4.3± 0.3	4.6± 0.5	4.3± 0.6	4.4± 0.6
0.5 ppm	4.9± 0.6	4.9± 0.7	4.9± 0.7	4.7± 0.5**	4.8± 1.1	4.5± 0.5	4.9± 1.1
1.5 ppm	4.1± 0.5**	4.1± 0.6*	4.2± 0.4**	3.9± 0.5*	4.0± 0.5*	3.9± 0.4**	4.0± 0.4**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 UNIT : g  
 REPORT TYPE : A1 26  
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)  
 ALL ANIMALS

Group Name	Administration week-day(effective)				
	22-7(7)	23-7(7)	24-7(7)	25-7(7)	26-7(7)
Control	4.4± 0.6	4.7± 0.9	4.3± 0.4	4.6± 0.4	4.6± 0.5
0.15 ppm	4.5± 0.4	4.4± 0.4	4.3± 0.4	4.6± 0.5	4.5± 0.6
0.5 ppm	4.7± 0.8	4.7± 0.7	4.6± 0.5*	4.5± 0.6	4.6± 0.5
1.5 ppm	4.1± 0.4	4.0± 0.5**	4.0± 0.4*	4.1± 0.5**	4.0± 0.5**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of Dunnett

TABLE F1

URINALYSIS : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE. TIME : 1  
 SEX : MALE

URINALYSIS

REPORT TYPE : A1

Group Name	NO. of Animals	pH_____							CHI	Protein_____					CHI	Glucose_____					CHI	Ketone body					CHI	Occult blood				CHI			
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-		±	+	2+
Control	21	0	0	0	0	2	3	16		0	9	8	4	0	0		21	0	0	0	0	0		1	12	6	0	2	0		21	0	0	0	0
0.15 ppm	24	0	0	0	0	2	1	21		2	8	8	6	0	0		24	0	0	0	0	0		4	8	7	5	0	0	*	24	0	0	0	0
0.5 ppm	21	0	0	0	0	2	5	14		0	2	12	6	1	0		21	0	0	0	0	0		1	9	4	5	2	0		21	0	0	0	0
1.5 ppm	20	0	1	0	0	2	3	14		1	7	11	1	0	0		20	0	0	0	0	0		0	14	5	1	0	0		20	0	0	0	0

Significant difference : \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of CHI SQUARE



STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
MEASURE. TIME : 1  
SEX : MALE

URINALYSIS

REPORT TYPE : A1

PAGE : 2

---

Group Name	NO. of Animals	Urobilinogen				CHI
		±	+	2+	3+ 4+	
Control	21	21	0	0	0	0
0.15 ppm	24	24	0	0	0	0
0.5 ppm	21	21	0	0	0	0
1.5 ppm	20	20	0	0	0	0

---

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of CHI SQUARE

**TABLE F2**

**URINALYSIS : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

URINALYSIS

Group Name	NO. of Animals	pH_____							CHI	Protein_____					CHI	Glucose_____					CHI	Ketone body					CHI	Occult blood				CHI			
		5.0	6.0	6.5	7.0	7.5	8.0	8.5		-	±	+	2+	3+		4+	-	±	+	2+		3+	4+	-	±	+		2+	3+	4+	-		±	+	2+
Control	21	0	1	4	2	7	5	2		5	15	1	0	0	0		21	0	0	0	0	0		1	15	4	1	0	0		21	0	0	0	0
0.15 ppm	21	0	0	1	4	5	9	2		12	9	0	0	0	0		21	0	0	0	0	0		4	16	1	0	0	0		21	0	0	0	0
0.5 ppm	20	0	0	1	2	5	10	2		5	14	1	0	0	0		20	0	0	0	0	0		3	17	0	0	0	0		20	0	0	0	0
1.5 ppm	23	0	0	1	1	3	11	7		11	11	1	0	0	0		23	0	0	0	0	0		6	16	1	0	0	0		23	0	0	0	0

Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of CHI SQUARE

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
MEASURE TIME : 1  
SEX : FEMALE REPORT TYPE : A1

URINALYSIS

---

Group Name	NO. of Animals	Urobilinogen				CHI
		±	+	2+	3+ 4+	
Control	21	21	0	0	0	0
0.15 ppm	21	21	0	0	0	0
0.5 ppm	20	20	0	0	0	0
1.5 ppm	23	23	0	0	0	0

---

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$

Test of CHI SQUARE

TABLE G1

HEMATOLOGY : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : MALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 1

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	23	11.09±	0.34	16.4±	0.5	46.0±	1.4	41.5±	0.5	14.8±	0.2	35.7±	0.6	1439±	120
0.15 ppm	23	11.03±	0.29	16.4±	0.4	45.9±	1.3	41.6±	0.5	14.9±	0.3	35.8±	0.5	1395±	160
0.5 ppm	24	11.22±	0.26	16.6±	0.3	46.8±	1.2	41.7±	0.7	14.8±	0.2	35.5±	0.5	1438±	75
1.5 ppm	24	11.24±	0.32	16.7±	0.4*	46.9±	1.5*	41.8±	0.6	14.9±	0.3	35.6±	0.5	1371±	103

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
MEASURE. TIME : 1  
SEX : MALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 2

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	23	3.0±	0.3
0.15 ppm	23	3.0±	0.1
0.5 ppm	24	3.0±	0.2
1.5 ppm	24	3.0±	0.2

---

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS6

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : MALE

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		$10^3/\mu\ell$		NEUTRO		LYMPHO							
Control	23	1.67±	0.50	37.0±	9.8	59.5±	9.9	1.9±	0.8	1.6±	1.5	0.0±	0.0
0.15 ppm	23	1.75±	1.12	35.6±	11.0	60.9±	10.5	2.1±	0.9	1.4±	1.4	0.0±	0.0
0.5 ppm	24	1.61±	0.79	34.3±	6.7	62.0±	6.4	1.8±	0.7	2.0±	1.7	0.0±	0.1
1.5 ppm	24	1.22±	0.60**	37.1±	8.8	60.1±	8.2	1.7±	0.9	1.1±	1.4	0.0±	0.0

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett



TABLE G2

HEMATOLOGY : FEMALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	RED BLOOD CELL 10 <sup>6</sup> /μl		HEMOGLOBIN g/dl		HEMATOCRIT %		MCV fl		MCH pg		MCHC g/dl		PLATELET 10 <sup>3</sup> /μl	
Control	25	10.79±	0.87	16.3±	1.0	44.8±	2.9	41.6±	1.3	15.2±	0.6	36.4±	0.7	1317±	123
0.15 ppm	24	10.84±	0.38	16.5±	0.5	45.3±	1.7	41.8±	0.6	15.2±	0.3	36.4±	0.6	1280±	91
0.5 ppm	25	10.79±	0.27	16.3±	0.4	45.3±	1.1	41.9±	0.7	15.1±	0.3	36.1±	0.6	1245±	158
1.5 ppm	24	10.98±	0.41	16.5±	0.5	45.7±	1.8	41.6±	0.5	15.1±	0.2	36.2±	0.8	1262±	126

Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
MEASURE. TIME : 1  
SEX : FEMALE

HEMATOLOGY (SUMMARY)  
ALL ANIMALS ( 27W)

REPORT TYPE : A1

PAGE : 5

---

Group Name	NO. of Animals	RETICULOCYTE %	
Control	25	3.0±	0.9
0.15 ppm	24	2.9±	0.7
0.5 ppm	25	3.2±	0.7
1.5 ppm	24	3.2±	1.1

---

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$

Test of Dunnett

(HCL070)

BAIS6

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	WBC		Differential		WBC (%)		MONO		EOSINO		BASO	
		10 <sup>3</sup> /μl		NEUTRO		LYMPHO							
Control	25	2.79±	1.88	39.1±	15.1	57.6±	13.9	2.2±	1.3	1.1±	1.4	0.0±	0.1
0.15 ppm	24	2.15±	1.61	35.4±	12.9	61.3±	12.0	2.3±	0.9	1.0±	1.1	0.0±	0.0
0.5 ppm	25	2.05±	1.12	39.8±	11.4	56.6±	10.4	2.3±	1.0	1.2±	1.4	0.0±	0.0
1.5 ppm	24	2.13±	1.23	39.4±	13.1	57.3±	12.4	2.2±	1.0	1.1±	0.9	0.0±	0.0

Significant difference : \* : P ≤ 0.05      \*\* : P ≤ 0.01      Test of Dunnett

**TABLE H1**

**BIOCHEMISTRY : MALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	24	5.2±	0.2	2.9±	0.1	1.3±	0.1	0.10±	0.01	230±	23	80±	10	56±	22
0.15 ppm	24	5.2±	0.2	2.9±	0.1	1.3±	0.1	0.10±	0.01	225±	28	80±	9	56±	17
0.5 ppm	25	5.0±	0.2*	2.8±	0.1	1.3±	0.1	0.10±	0.01	221±	24	75±	9	57±	17
1.5 ppm	24	5.1±	0.1	2.9±	0.1	1.3±	0.1	0.11±	0.01**	201±	17**	63±	8**	38±	12**

Significant difference ; \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE. TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	24	166±	19	66±	18	25±	12	296±	62	198±	14	0.2±	0.3	89±	46
0.15 ppm	24	167±	18	76±	24	30±	16	312±	73	199±	22	0.3±	0.4	94±	33
0.5 ppm	25	159±	17	61±	17	23±	14	282±	70	194±	16	0.3±	0.3	93±	39
1.5 ppm	24	135±	18**	70±	13	20±	4	293±	72	213±	25**	0.2±	0.2	138±	156

Significant difference ; \* :  $P \leq 0.05$

\*\* :  $P \leq 0.01$

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : MALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	UREANITROGEN		SODIUM		POTASSIUM		CHLORIDE		CALCIUM		INORGANIC PHOSPHRUS	
		mg/dl		mEq/l		mEq/l		mEq/l		mg/dl		mg/dl	
Control	24	24.1±	6.3	149±	1	3.5±	0.3	118±	1	8.6±	0.2	5.3±	0.7
0.15 ppm	24	23.4±	4.8	149±	1	3.6±	0.2	118±	2	8.5±	0.1	5.6±	0.8
0.5 ppm	25	24.3±	5.3	149±	1	3.7±	0.3	118±	2	8.6±	0.3	5.4±	0.8
1.5 ppm	24	22.9±	3.6	149±	1	3.8±	0.3**	118±	2	8.6±	0.1	5.3±	0.9

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett



**TABLE H2**

**BIOCHEMISTRY : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : FEMALE

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

REPORT TYPE : A1

Group Name	NO. of Animals	TOTAL PROTEIN g/dl		ALBUMIN g/dl		A/G RATIO		T-BILIRUBIN mg/dl		GLUCOSE mg/dl		T-CHOLESTEROL mg/dl		TRIGLYCERIDE mg/dl	
Control	25	5.2±	0.2	3.1±	0.1	1.5±	0.1	0.10±	0.02	207±	25	67±	9	47±	16
0.15 ppm	24	5.3±	0.2	3.1±	0.1	1.5±	0.1	0.09±	0.01	204±	25	64±	7	41±	17
0.5 ppm	24	5.3±	0.2	3.1±	0.1	1.4±	0.1	0.10±	0.01	206±	24	66±	8	42±	14
1.5 ppm	25	5.3±	0.3	3.1±	0.3	1.4±	0.1	0.11±	0.05	197±	40	65±	19	37±	13

Significant difference ; \* : P ≤ 0.05

\*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl		AST U/L		ALT U/L		LDH U/L		ALP U/L		G-GTP U/L		CK U/L	
Control	25	138±	17	117±	89	40±	46	279±	163	322±	35	0.2±	0.2	124±	82
0.15 ppm	24	131±	16	96±	48	29±	20	256±	71	322±	35	0.2±	0.2	93±	27
0.5 ppm	24	136±	17	114±	43	32±	16	291±	156	332±	46	0.3±	0.3	115±	52
1.5 ppm	25	128±	16	90±	35	26±	14	266±	132	340±	39	0.3±	0.4	155±	223

Significant difference : \* : P ≤ 0.05      \*\* : P ≤ 0.01

Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 MEASURE TIME : 1  
 SEX : FEMALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)  
 ALL ANIMALS ( 27W)

Group Name	NO. of Animals	UREANITROGEN		SODIUM		POTASSIUM		CHLORIDE		CALCIUM		INORGANIC PHOSPHRUS	
		mg/dl		mEq/l		mEq/l		mEq/l		mg/dl		mg/dl	
Control	25	18.7±	3.0	149±	2	3.2±	0.3	118±	2	8.9±	0.2	5.3±	1.0
0.15 ppm	24	17.7±	2.6	149±	2	3.1±	0.3	118±	2	8.8±	0.2	5.4±	0.8
0.5 ppm	24	18.5±	2.5	149±	2	3.2±	0.2	119±	2	8.9±	0.2	5.4±	0.8
1.5 ppm	25	21.6±	12.8	149±	2	3.5±	0.6*	118±	3	8.9±	0.3	5.3±	1.3

Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01

Test of Dunnett

TABLE I1

GROSS FINDINGS : MALE

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
REPORT TYPE : A1  
SEX : MALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

Organ	Findings	Group Name NO. of Animals	Control					
			25	(%)	25	(%)		
			0.15 ppm		0.5 ppm		1.5 ppm	
			25	(%)	25	(%)	25	(%)
lung	red		0	( 0)	0	( 0)	0	( 0)
	white zone		2	( 8)	1	( 4)	2	( 8)
	nodule		1	( 4)	2	( 8)	4	(16)
lymph node	enlarged		0	( 0)	0	( 0)	0	( 0)
thymus	enlarged		0	( 0)	0	( 0)	0	( 0)
spleen	enlarged		0	( 0)	0	( 0)	0	( 0)
	black zone		3	(12)	3	(12)	8	(32)
	nodule		1	( 4)	1	( 4)	0	( 0)
salivary gl	nodule		1	( 4)	0	( 0)	0	( 0)
stomach	forestomach:nodule		0	( 0)	0	( 0)	0	( 0)
	forestomach:thick		1	( 4)	0	( 0)	1	( 4)
	glandular stomach:thick		2	( 8)	1	( 4)	5	(20)
liver	white zone		1	( 4)	0	( 0)	3	(12)
	red zone		0	( 0)	0	( 0)	1	( 4)
	nodule		0	( 0)	0	( 0)	1	( 4)
kidney	white zone		1	( 4)	0	( 0)	0	( 0)
testis	small		1	( 4)	0	( 0)	0	( 0)
	red zone		0	( 0)	1	( 4)	0	( 0)
pleura	red zone		1	( 4)	0	( 0)	0	( 0)
abdominal c	hemorrhage		0	( 0)	1	( 4)	0	( 0)
thoracic ca	pleural fluid		1	( 4)	0	( 0)	0	( 0)

**TABLE I2**

**GROSS FINDINGS : FEMALE**

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
REPORT TYPE : A1  
SEX : FEMALE

GROSS FINDINGS (SUMMARY)  
ALL ANIMALS (0- 27W)

PAGE : 2

Organ	Findings	Group Name NO. of Animals	Control					
			25	(%)	25	(%)		
			0.15 ppm		0.5 ppm		1.5 ppm	
			25	(%)	25	(%)	25	(%)
skin/app	nodule		0	( 0)	1	( 4)	0	( 0)
lung	white zone		0	( 0)	0	( 0)	3	( 12)
	nodule		2	( 8)	1	( 4)	1	( 4)
spleen	enlarged		1	( 4)	0	( 0)	0	( 0)
	white zone		1	( 4)	0	( 0)	0	( 0)
	black zone		5	( 20)	4	( 16)	3	( 12)
	nodule		2	( 8)	1	( 4)	2	( 8)
stomach	forestomach:nodule		2	( 8)	2	( 8)	0	( 0)
	forestomach:thick		1	( 4)	1	( 4)	1	( 4)
	glandular stomach:thick		8	( 32)	5	( 20)	8	( 32)
liver	black zone		1	( 4)	0	( 0)	0	( 0)
	nodule		1	( 4)	0	( 0)	0	( 0)
ovary	enlarged		0	( 0)	1	( 4)	1	( 4)
uterus	nodule		1	( 4)	0	( 0)	0	( 0)
vagina	nodule		0	( 0)	0	( 0)	0	( 0)
thoracic ca	pleural fluid		0	( 0)	1	( 4)	0	( 0)



TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	ADRENALS		TESTES		HEART		LUNGS		KIDNEYS	
Control	24	29.8± 3.3	0.014±	0.004	0.224±	0.037	0.197±	0.018	0.167±	0.017	0.606±	0.046
0.15 ppm	24	29.5± 2.7	0.014±	0.002	0.242±	0.053	0.197±	0.019	0.166±	0.017	0.604±	0.057
0.5 ppm	25	29.6± 2.9	0.013±	0.002	0.237±	0.045	0.190±	0.018	0.171±	0.013	0.586±	0.040
1.5 ppm	24	25.4± 1.9**	0.013±	0.004	0.236±	0.036	0.169±	0.017**	0.160±	0.018	0.547±	0.055**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	24	0.072±	0.027	1.351±	0.126	0.473±	0.013
0.15 ppm	24	0.071±	0.012	1.333±	0.125	0.476±	0.014
0.5 ppm	25	0.068±	0.009	1.293±	0.096	0.476±	0.014
1.5 ppm	24	0.062±	0.012	1.135±	0.106**	0.469±	0.020

Significant difference ; \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

**TABLE J2**

**ORGAN WEIGHT, ABSOLUTE : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight	ADRENALS		OVARIES		HEART		LUNGS		KIDNEYS	
Control	25	22.1 ± 1.9	0.016 ±	0.002	0.026 ±	0.005	0.149 ±	0.014	0.163 ±	0.022	0.427 ±	0.031
0.15 ppm	24	22.2 ± 1.6	0.015 ±	0.002	0.030 ±	0.015	0.148 ±	0.012	0.161 ±	0.013	0.420 ±	0.037
0.5 ppm	25	21.7 ± 1.7	0.015 ±	0.002	0.027 ±	0.005	0.152 ±	0.017	0.165 ±	0.017	0.427 ±	0.037
1.5 ppm	25	20.9 ± 2.3	0.015 ±	0.003	0.026 ±	0.006	0.137 ±	0.014*	0.189 ±	0.138	0.395 ±	0.038**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN		LIVER		BRAIN	
Control	25	0.107±	0.095	1.134±	0.155	0.499±	0.015
0.15 ppm	24	0.091±	0.017	1.105±	0.095	0.494±	0.015
0.5 ppm	25	0.091±	0.035	1.098±	0.112	0.493±	0.012
1.5 ppm	25	0.078±	0.018	0.996±	0.106**	0.486±	0.014**

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

(HCL040)

BAIS 6

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
REPORT TYPE : A1  
SEX : MALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	24	29.8± 3.3	0.049± 0.016	0.758± 0.130	0.667± 0.061	0.569± 0.084	2.047± 0.176
0.15 ppm	24	29.5± 2.7	0.046± 0.007	0.829± 0.213	0.669± 0.050	0.564± 0.044	2.046± 0.112
0.5 ppm	25	29.6± 2.9	0.044± 0.008	0.806± 0.165	0.643± 0.042	0.583± 0.054	1.988± 0.131
1.5 ppm	24	25.4± 1.9**	0.051± 0.015	0.934± 0.151**	0.668± 0.052	0.634± 0.064**	2.158± 0.166*

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett



STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	24	0.245 ± 0.101	4.549 ± 0.255	1.606 ± 0.168
0.15 ppm	24	0.241 ± 0.035	4.514 ± 0.186	1.623 ± 0.128
0.5 ppm	25	0.230 ± 0.032	4.384 ± 0.211	1.624 ± 0.152
1.5 ppm	24	0.244 ± 0.043	4.473 ± 0.217	1.856 ± 0.130**

Significant difference : \* :  $P \leq 0.05$     \*\* :  $P \leq 0.01$                       Test of Dunnett

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE  
 UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
 SURVIVAL ANIMALS ( 27W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	25	22.1± 1.9	0.073± 0.010	0.120± 0.017	0.672± 0.038	0.739± 0.079	1.933± 0.113
0.15 ppm	24	22.2± 1.6	0.067± 0.008	0.135± 0.076	0.668± 0.038	0.726± 0.046	1.891± 0.095
0.5 ppm	25	21.7± 1.7	0.071± 0.011	0.124± 0.021	0.703± 0.065	0.764± 0.080	1.968± 0.122
1.5 ppm	25	20.9± 2.3	0.071± 0.012	0.126± 0.028	0.660± 0.056	0.937± 0.833	1.898± 0.141

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
REPORT TYPE : A1  
SEX : FEMALE  
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)  
SURVIVAL ANIMALS ( 27W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	25	0.467 ± 0.334	5.114 ± 0.320	2.270 ± 0.166
0.15 ppm	24	0.408 ± 0.065	4.970 ± 0.202	2.232 ± 0.124
0.5 ppm	25	0.417 ± 0.142	5.054 ± 0.209	2.284 ± 0.155
1.5 ppm	25	0.374 ± 0.077	4.777 ± 0.276**	2.346 ± 0.199

Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$  Test of Dunnett

(HCL042)

BAIS 6

TABLE L1

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	0.15 ppm 25	0.5 ppm 25	1.5 ppm 25
[Respiratory system]						
lung	bronchiolar-alveolar adenoma		<25> 2 ( 8%)	<25> 6 ( 24%)	<25> 6 ( 24%)	<25> 3 ( 12%)
	hemangioma		1 ( 4%)	0 ( 0%)	0 ( 0%)	0 ( 0%)
	bronchiolar-alveolar carcinoma		0 ( 0%)	1 ( 4%)	5 ( 20%)	0 ( 0%)
[Hematopoietic system]						
lymph node	malignant lymphoma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
spleen	hemangioma		<25> 2 ( 8%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)
	hemangiosarcoma		0 ( 0%)	1 ( 4%)	0 ( 0%)	0 ( 0%)
[Digestive system]						
salivary gl	hemangioma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)
liver	hepatocellular adenoma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 5 ( 20%)	<25> 1 ( 4%)
[Special sense organs/appendage]						
Harder gl	adenoma		<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)
[Musculoskeletal system]						
muscle	hemangioma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	0.15 ppm 25	0.5 ppm 25	1.5 ppm 25
[Body cavities]						
pleura	hemangiosarcoma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

**TABLE L2**

**HISTOPATHOLOGICAL FINDINGS :**

**NEOPLASTIC LESIONS : FEMALE**



STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	0.15 ppm 25	0.5 ppm 25	1.5 ppm 25
{Integumentary system/appandage}						
skin/app	squamous cell papilloma		<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 1 ( 4%)
{Respiratory system}						
nasal cavit	papilloma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
lung	bronchiolar-alveolar adenoma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 4 ( 16%)	<25> 1 ( 4%)
	bronchiolar-alveolar carcinoma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 2 ( 8%)
{Hematopoietic system}						
spleen	hemangioma		<25> 3 ( 12%)	<25> 3 ( 12%)	<25> 3 ( 12%)	<25> 0 ( 0%)
	hemangiosarcoma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)
{Digestive system}						
stomach	squamous cell papilloma		<25> 1 ( 4%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 1 ( 4%)
liver	hemangioma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)
{Reproductive system}						
uterus	endometrial stromal sarcoma		<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of animals on Study	Control 25	0.15 ppm 25	0.5 ppm 25	1.5 ppm 25
{Special sense organs/appendage}						
Harder gl	adenoma		<25> 1 ( 4%)	<25> 1 ( 4%)	<25> 2 ( 8%)	<25> 0 ( 0%)
{Musculoskeletal system}						
muscle	hemangioma		<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 0 ( 0%)	<25> 1 ( 4%)
{Body cavities}						
pleura	hemangiosarcoma		<25> 0 ( 0%)	<25> 1 ( 4%)	<25> 0 ( 0%)	<25> 0 ( 0%)

< a > a : Number of animals examined at the site  
 b ( c ) b : Number of animals with neoplasm c : b / a \* 100

TABLE M1

NEOPLASTIC LESIONS-INCIDENCE AND  
STATISTICAL ANALYSIS : MALE

STUDY No. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 SEX : MALE REPORT TYPE : A1

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	2/25 ( 8.0)	6/25 ( 24.0)	6/25 ( 24.0)	3/25 ( 12.0)
Adjusted rates(b)	8.33	24.00	24.00	12.50
Terminal rates(c)	2/24 ( 8.3)	5/24 ( 20.8)	6/25 ( 24.0)	3/24 ( 12.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6085			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.7370			
Fisher Exact test(e)		P = 0.1234	P = 0.1234	P = 0.5000
SITE : lung				
TUMOR : bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	0/25 ( 0.0)	1/25 ( 4.0)	5/25 ( 20.0)	0/25 ( 0.0)
Adjusted rates(b)	0.00	4.17	20.00	0.00
Terminal rates(c)	0/24 ( 0.0)	1/24 ( 4.2)	5/25 ( 20.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6351			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.6787			
Fisher Exact test(e)		P = 0.5000	P = 0.0251*	P = N. C.
SITE : spleen				
TUMOR : hemangioma				
Tumor rate				
Overall rates(a)	2/25 ( 8.0)	1/25 ( 4.0)	0/25 ( 0.0)	0/25 ( 0.0)
Adjusted rates(b)	8.33	4.17	0.00	0.00
Terminal rates(c)	2/24 ( 8.3)	1/24 ( 4.2)	0/25 ( 0.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9551			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1425			
Fisher Exact test(e)		P = 0.5000	P = 0.2449	P = 0.2449

STUDY No. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 SEX : MALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
SITE : liver				
TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	1/25 ( 4.0)	0/25 ( 0.0)	5/25 ( 20.0)	1/25 ( 4.0)
Adjusted rates(b)	4.17	0.00	20.00	4.17
Terminal rates(c)	1/24 ( 4.2)	0/24 ( 0.0)	5/25 ( 20.0)	1/24 ( 4.2)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4176			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8735			
Fisher Exact test(e)		P = 0.5000	P = 0.0947	P = 0.7551
SITE : ALL SITE				
TUMOR : hemangioma				
Tumor rate				
Overall rates(a)	3/25 ( 12.0)	1/25 ( 4.0)	0/25 ( 0.0)	0/25 ( 0.0)
Adjusted rates(b)	8.33	4.17	0.00	0.00
Terminal rates(c)	2/24 ( 8.3)	1/24 ( 4.2)	0/25 ( 0.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.9551			
Combined analysis(d)	P = 0.9813			
Cochran-Armitage test(e)	P = 0.0808			
Fisher Exact test(e)		P = 0.3046	P = 0.1173	P = 0.1173
SITE : ALL SITE				
TUMOR : hemangioma, hemangiosarcoma				
Tumor rate				
Overall rates(a)	3/25 ( 12.0)	2/25 ( 8.0)	0/25 ( 0.0)	0/25 ( 0.0)
Adjusted rates(b)	8.33	4.17	0.00	0.00
Terminal rates(c)	2/24 ( 8.3)	1/24 ( 4.2)	0/25 ( 0.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.8745			
Prevalence method(d)	P = 0.9551			
Combined analysis(d)	P = 0.9856			
Cochran-Armitage test(e)	P = 0.0609			
Fisher Exact test(e)		P = 0.5000	P = 0.1173	P = 0.1173

STUDY No. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 SEX : MALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	2/25 ( 8.0)	7/25 ( 28.0)	9/25 ( 36.0)	3/25 ( 12.0)
Adjusted rates(b)	8.33	28.00	36.00	12.50
Terminal rates(c)	2/24 ( 8.3)	6/24 ( 25.0)	9/25 ( 36.0)	3/24 ( 12.5)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.6783			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.6032			
Fisher Exact test(e)		P = 0.0692	P = 0.0187*	P = 0.5000
SITE : spleen				
TUMOR : hemangioma, hemangiosarcoma				
Tumor rate				
Overall rates(a)	2/25 ( 8.0)	2/25 ( 8.0)	0/25 ( 0.0)	0/25 ( 0.0)
Adjusted rates(b)	8.33	4.17	0.00	0.00
Terminal rates(c)	2/24 ( 8.3)	1/24 ( 4.2)	0/25 ( 0.0)	0/24 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5359			
Prevalence method(d)	P = 0.9551			
Combined analysis(d)	P = 0.9673			
Cochran-Armitage test(e)	P = 0.1063			
Fisher Exact test(e)		P = 0.6954	P = 0.2449	P = 0.2449

(HPT360A)

BAIS6

(a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N.C. : Statistical value cannot be calculated and was not significant.

**TABLE M2**

**NEOPLASTIC LESIONS-INCIDENCE AND  
STATISTICAL ANALYSIS : FEMALE**

STUDY No. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 SEX : FEMALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma				
Tumor rate				
Overall rates(a)	1/25 ( 4.0)	0/25 ( 0.0)	4/25 ( 16.0)	1/25 ( 4.0)
Adjusted rates(b)	4.00	0.00	16.00	4.00
Terminal rates(c)	1/25 ( 4.0)	0/24 ( 0.0)	4/25 ( 16.0)	1/25 ( 4.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.4094			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.8430			
Fisher Exact test(e)		P = 0.5000	P = 0.1743	P = 0.7551
SITE : lung				
TUMOR : bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	1/25 ( 4.0)	0/25 ( 0.0)	1/25 ( 4.0)	2/25 ( 8.0)
Adjusted rates(b)	4.00	0.00	4.00	8.00
Terminal rates(c)	1/25 ( 4.0)	0/24 ( 0.0)	1/25 ( 4.0)	2/25 ( 8.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1368			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.2386			
Fisher Exact test(e)		P = 0.5000	P = 0.7551	P = 0.5000
SITE : spleen				
TUMOR : hemangioma				
Tumor rate				
Overall rates(a)	3/25 ( 12.0)	3/25 ( 12.0)	3/25 ( 12.0)	0/25 ( 0.0)
Adjusted rates(b)	12.00	12.50	12.00	0.00
Terminal rates(c)	3/25 ( 12.0)	3/24 ( 12.5)	3/25 ( 12.0)	0/25 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9681			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0843			
Fisher Exact test(e)		P = 0.6664	P = 0.6664	P = 0.1173



STUDY No. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 SEX : FEMALE REPORT TYPE : A1

NEOPLASTIC LESIONS--INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
SITE : Harderian gland TUMOR : adenoma				
Tumor rate				
Overall rates(a)	1/25 ( 4.0)	1/25 ( 4.0)	2/25 ( 8.0)	0/25 ( 0.0)
Adjusted rates(b)	4.00	4.17	8.00	0.00
Terminal rates(c)	1/25 ( 4.0)	1/24 ( 4.2)	2/25 ( 8.0)	0/25 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.7944			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.3827			
Fisher Exact test(e)		P = 0.7551	P = 0.5000	P = 0.5000
SITE : ALL SITE TUMOR : hemangioma				
Tumor rate				
Overall rates(a)	4/25 ( 16.0)	3/25 ( 12.0)	3/25 ( 12.0)	1/25 ( 4.0)
Adjusted rates(b)	16.00	12.00	12.00	4.00
Terminal rates(c)	4/25 ( 16.0)	3/24 ( 12.5)	3/25 ( 12.0)	1/25 ( 4.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9175			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.1782			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.1743
SITE : ALL SITE TUMOR : hemangioma, hemangiosarcoma				
Tumor rate				
Overall rates(a)	4/25 ( 16.0)	4/25 ( 16.0)	3/25 ( 12.0)	1/25 ( 4.0)
Adjusted rates(b)	16.00	12.50	12.00	4.00
Terminal rates(c)	4/25 ( 16.0)	3/24 ( 12.5)	3/25 ( 12.0)	1/25 ( 4.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5339			
Prevalence method(d)	P = 0.9175			
Combined analysis(d)	P = 0.9389			
Cochran-Armitage test(e)	P = 0.1335			
Fisher Exact test(e)		P = 0.6490	P = 0.5000	P = 0.1743

STUDY No. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 SEX : FEMALE REPORT TYPE : A1

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
SITE : lung				
TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	2/25 ( 8.0)	0/25 ( 0.0)	5/25 ( 20.0)	3/25 ( 12.0)
Adjusted rates(b)	8.00	0.00	20.00	12.00
Terminal rates(c)	2/25 ( 8.0)	0/24 ( 0.0)	5/25 ( 20.0)	3/25 ( 12.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.1864			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.3541			
Fisher Exact test(e)		P = 0.2449	P = 0.2087	P = 0.5000
SITE : spleen				
TUMOR : hemangioma, hemangiosarcoma				
Tumor rate				
Overall rates(a)	4/25 ( 16.0)	3/25 ( 12.0)	3/25 ( 12.0)	0/25 ( 0.0)
Adjusted rates(b)	16.00	12.00	12.00	0.00
Terminal rates(c)	4/25 ( 16.0)	3/24 ( 12.5)	3/25 ( 12.0)	0/25 ( 0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9835			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0508			
Fisher Exact test(e)		P = 0.5000	P = 0.5000	P = 0.0549

(HPT360A)

BAIS6

(a): Number of tumor-bearing animals/number of animals examined at the site.  
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.  
 (c): Observed tumor incidence at terminal kill.  
 (d): Beneath the control incidence are the P-values associated with the trend test.  
 Standard method : Death analysis  
 Prevalence method : Incidental tumor test  
 Combined analysis : Death analysis + Incidental tumor test  
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.  
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.  
 ----- : There is no data which should be statistical analysis.  
 Significant difference : \* :  $P \leq 0.05$  \*\* :  $P \leq 0.01$   
 N.C. : Statistical value cannot be calculated and was not significant.

TABLE N1

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC  
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER :

Jic:CB6F1-Tg rasH2@Jcl MALE MICE

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN  
 BIOASSAY RESEARCH CENTER : Jic:CB6F1-Tg rasH2@Jcl MALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. – Max. (%)
Lung	150			
Bronchiolar-alveolar adenoma (A)		9	6.0	0 – 12
Bronchiolar-alveolar carcinoma (B)		0	0	0
A+B		9	6.0	0 – 12
Liver				
Hepatocellular adenoma	150	1	0.7	0 – 4

6 carcinogenicity studies examined in Japan Bioassay Research Center were used.  
 Study No. : 0886, 0887, 0900, 0905, 0912, 0919

TABLE N2

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC  
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER :

Jic:CB6F1-Tg rasH2@Jcl FEMALE MICE

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN  
 BIOASSAY RESEARCH CENTER : Jic:CB6F1-Tg rasH2@Jcl FEMALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. – Max. (%)
Lung	150			
Bronchiolar-alveolar adenoma (A)		6	4.0	0 – 12
Bronchiolar-alveolar carcinoma (B)		4	2.7	0 – 8
A+B		10	6.7	0 – 16
Nasal cavity				
Papilloma	150	0	0	0

6 carcinogenicity studies examined in Japan Bioassay Research Center were used.  
 Study No. : 0886, 0887, 0901, 0905, 0913, 0919

**TABLE O**

**HISTOPATHOLOGICAL FINDINGS :**

**METASTASIS OF TUMOR : MALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	0.15 ppm 25	0.5 ppm 25	1.5 ppm 25
[Respiratory system]						
nasal cavit	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
lung	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
[Hematopoietic system]						
bone marrow	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
thymus	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
spleen	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
[Digestive system]						
liver	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
[Urinary system]						
kidney	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
urin bladd	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
[Endocrine system]						
adrenal	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1

< a > a : Number of animals examined at the site  
 b : Number of animals with lesion



STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study	Control 25	0.15 ppm 25	0.5 ppm 25	1.5 ppm 25
[Reproductive system]						
epididymis	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
[Special sense organs/appendage]						
eye	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
Harder gl	leukemic cell infiltration		<25> 0	<25> 0	<25> 0	<25> 1
< a >	a : Number of animals examined at the site					
b	b : Number of animals with lesion					

TABLE P1

HISTOPATHOLOGICAL FINDINGS :  
NON-NEOPLASTIC LESIONS : MALE

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																		
nasal cavit	hyperkeratosis		<25>				<25>				<25>				<25>			
		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	
		( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	
	eosinophilic change:olfactory epithelium	7	9	0	0	6	6	0	0	8	7	0	0	1	2	0	0 **	
		( 28)	( 36)	( 0)	( 0)	( 24)	( 24)	( 0)	( 0)	( 32)	( 28)	( 0)	( 0)	( 4)	( 8)	( 0)	( 0)	
	eosinophilic change:respiratory epithelium	11	5	0	0	10	5	0	0	10	4	0	0	8	0	0	0 *	
		( 44)	( 20)	( 0)	( 0)	( 40)	( 20)	( 0)	( 0)	( 40)	( 16)	( 0)	( 0)	( 32)	( 0)	( 0)	( 0)	
	respiratory metaplasia:olfactory epithelium	1	0	0	0	0	0	0	0	0	0	0	0	8	1	0	0 *	
		( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 32)	( 4)	( 0)	( 0)	
	respiratory metaplasia:gland	18	7	0	0	21	3	0	0	22	3	0	0	21	4	0	0	
		( 72)	( 28)	( 0)	( 0)	( 84)	( 12)	( 0)	( 0)	( 88)	( 12)	( 0)	( 0)	( 84)	( 16)	( 0)	( 0)	
	transitional cell hyperplasia	0	0	0	0	0	0	0	0	14	11	0	0 **	12	13	0	0 **	
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 56)	( 44)	( 0)	( 0)	( 48)	( 52)	( 0)	( 0)	
	atrophy:olfactory epithelium	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0 *	
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 28)	( 0)	( 0)	( 0)	
nasopharynx	eosinophilic change:respiratory epithelium		<25>				<25>				<25>				<25>			
		20	0	0	0	19	0	0	0	16	0	0	0	5	0	0	0 **	
		( 80)	( 0)	( 0)	( 0)	( 76)	( 0)	( 0)	( 0)	( 64)	( 0)	( 0)	( 0)	( 20)	( 0)	( 0)	( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																	
lung	eosinophilic crystalline pneumonia	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Hematopoietic system]																	
thymus	ultimobranchial body remanet	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
spleen	deposit of melanin	3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	8 ( 32)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 16)	0 ( 0)	0 ( 0)
	extramedullary hematopoiesis	3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	
[Circulatory system]																	
heart	mineralization	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Digestive system]																	
stomach																	
	ulcer:forestomach	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
	hyperplasia:forestomach	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)
	erosion:glandular stomach	2 ( 8)	1 ( 4)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
	ulcer:glandular stomach	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
	hyperplasia:glandular stomach	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
liver																	
	angiectasis	<25>				<25>				<25>				<25>			
		0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	necrosis:focal	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	fatty change:central	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control				0.15 ppm				0.5 ppm				1.5 ppm			
		No. of Animals on Study				No. of Animals on Study				No. of Animals on Study				No. of Animals on Study			
Grade		1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+	1+	2+	3+	4+
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
[Digestive system]																	
liver																	
	granulation	<25>				<25>				<25>				<25>			
		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)
	acidophilic cell focus	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
	basophilic cell focus	2	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0
		( 8)	( 4)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)
[Urinary system]																	
kidney																	
	regeneration:proximal tubule	<25>				<25>				<25>				<25>			
		0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)
[Endocrine system]																	
pituitary																	
	Rathke pouch	<25>				<25>				<25>				<25>			
		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Endocrine system]																	
parathyroid	ultimobranchial body remanet	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)
[Reproductive system]																	
testis	tubular atrophy	1 ( 4)	1 ( 4)	0 ( 0)	0 ( 0)	2 ( 8)	1 ( 4)	1 ( 4)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
epididymis	inflammatory infiltration	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	spermatogenic granuloma	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	debris of spermatic elements	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
[Special sense organs/appendage]																	
Harder gl	hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Group Name No. of Animals on Study Grade	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)

{Musculoskeletal system}

bone	necrosis:focal		<25>				<25>				<25>				<25>			
			0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
			( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square



**TABLE P2**

**HISTOPATHOLOGICAL FINDINGS :**  
**NON-NEOPLASTIC LESIONS : FEMALE**

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25				
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																		
nasal caviti																		
	exudate		<25>				<25>				<25>				<25>			
		0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)
	eosinophilic change:olfactory epithelium	13	11	0	0	15	9	0	0	13	6	0	0	11	5	0	0 *	
		( 52)	( 44)	( 0)	( 0)	( 60)	( 36)	( 0)	( 0)	( 52)	( 24)	( 0)	( 0)	( 44)	( 20)	( 0)	( 0)	
	eosinophilic change:respiratory epithelium	13	12	0	0	11	13	1	0	7	14	0	0	10	11	0	0	
		( 52)	( 48)	( 0)	( 0)	( 44)	( 52)	( 4)	( 0)	( 28)	( 56)	( 0)	( 0)	( 40)	( 44)	( 0)	( 0)	
	respiratory metaplasia:olfactory epithelium	0	0	0	0	0	0	0	0	0	0	0	0	5	1	0	0 *	
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 20)	( 4)	( 0)	( 0)	
	respiratory metaplasia:gland	19	6	0	0	13	10	2	0	16	6	2	0	11	13	1	0	
		( 76)	( 24)	( 0)	( 0)	( 52)	( 40)	( 8)	( 0)	( 64)	( 24)	( 8)	( 0)	( 44)	( 52)	( 4)	( 0)	
	transitional cell hyperplasia	0	0	0	0	0	0	0	0	16	3	0	0 **	15	8	0	0 **	
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 64)	( 12)	( 0)	( 0)	( 60)	( 32)	( 0)	( 0)	
	atrophy:olfactory epithelium	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	0	
		( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 0)	( 4)	( 0)	( 0)	( 0)	( 8)	( 0)	( 0)	( 0)	
nasopharynx																		
	eosinophilic change:respiratory epithelium		<25>				<25>				<25>				<25>			
		25	0	0	0	25	0	0	0	22	0	0	0	24	0	0	0	
		(100)	( 0)	( 0)	( 0)	(100)	( 0)	( 0)	( 0)	( 88)	( 0)	( 0)	( 0)	( 96)	( 0)	( 0)	( 0)	

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control No. of Animals on Study Grade				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Respiratory system]																	
lung	hemorrhage	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	fibrosis:focal	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
	bronchiolar-alveolar cell hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
[Hematopoietic system]																	
spleen	deposit of melanin	6 ( 24)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)
	extramedullary hematopoiesis	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
[Digestive system]																	
stomach	erosion:forestomach	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Digestive system}																	
stomach	hyperplasia:forestomach	4 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	erosion:glandular stomach	7 ( 28)	0 ( 0)	0 ( 0)	0 ( 0)	3 ( 12)	0 ( 0)	0 ( 0)	0 ( 0)	5 ( 20)	0 ( 0)	0 ( 0)	0 ( 0)	4 ( 16)	0 ( 0)	0 ( 0)	0 ( 0)
	hyperplasia:glandular stomach	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
liver	inflammatory cell nest	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)
	basophilic cell focus	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
{Urinary system}																	
kidney	regeneration:proximal tubule	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference ; \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

STUDY NO. : 0926  
 ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
 REPORT TYPE : A1  
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)  
 ALL ANIMALS (0- 27W)

Organ	Findings	Control 25				0.15 ppm 25				0.5 ppm 25				1.5 ppm 25			
		1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
[Endocrine system]																	
parathyroid	ultimobranchial body remanet	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
[Reproductive system]																	
ovary	thrombus	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)
uterus	cystic endometrial hyperplasia	11 ( 44)	0 ( 0)	0 ( 0)	0 ( 0)	14 ( 56)	0 ( 0)	0 ( 0)	0 ( 0)	12 ( 48)	0 ( 0)	0 ( 0)	0 ( 0)	10 ( 40)	0 ( 0)	0 ( 0)	0 ( 0)
[Special sense organs/appendage]																	
Harder gl	hyperplasia	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	2 ( 8)	0 ( 0)	0 ( 0)	0 ( 0)
[Musculoskeletal system]																	
bone	necrosis:focal	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	1 ( 4)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)	0 ( 0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe  
 < a > a : Number of animals examined at the site  
 b : Number of animals with lesion  
 ( c ) c : b / a \* 100  
 Significant difference : \* : P ≤ 0.05 \*\* : P ≤ 0.01 Test of Chi Square

TABLE Q1

CAUSE OF DEATH : MALE

STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
SEX : MALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

---

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
Number of Dead and Moribund Animal	1	1	0	1
tumor d:leukemia	0	0	0	1
tumor d:spleen	0	1	0	0
tumor d:thoracic cav	1	0	0	0

---

(B10120)

BAIS6

TABLE Q2

CAUSE OF DEATH : FEMALE



STUDY NO. : 0926  
ANIMAL : CByB6F1-Tg(HRAS)2Jic (tg/wt)  
SEX : FEMALE

COUSE OF DEATH (SUMMARY)  
(0- 27W)

Group Name	Control	0.15 ppm	0.5 ppm	1.5 ppm
Number of Dead and Moribund Animal	0	1	0	0
tumor d:pleura	0	1	0	0

(B10120)

BAIS6